Synergetics USA Inc. (SURG: Quote) is gaining ground on FDA news. Shares are up $1.09, or 28 percent, to $4.94.
The company said it received 510(k) clearance from the U.S. Food and Drug Administration for VersaVIT, a novel vitrectomy system for the retinal surgery market.
"The entry of VersaVIT into the global vitrectomy market is a major milestone in Synergetics' strategy to enter into higher growth areas of retinal surgery," said David Hable, President and CEO.
The company is awaiting CE mark approval, which has been submitted and is currently under review.
Synergetics is a medical device company that makes innovative microsurgical devices for ophthalmic and neurosurgical applications.
Click here to receive FREE breaking news email alerts for Synergetics USA Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com